<DOC>
	<DOCNO>NCT00948220</DOCNO>
	<brief_summary>One single study suggest bone mineral density ( BMD ) reduce patient non-cirrhotic chronic viral hepatitis C. Antiviral combination therapy standard interferon ribavirin may decrease BMD . The aim study systematically investigate effect chronic hepatitis C genotype 1 infection alone current standard therapy peginterferon alfa-2a/ribavirin BMD bone metabolism .</brief_summary>
	<brief_title>Influence Antiviral Therapy Bone Mineral Density Metabolism Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>proven chronic hepatitis C age 18 65 male patient high grade liver fibrosis ( Grade 3 4 ) renal disease hyperparathyroidism hypogonadism malignant disease use drug know effect bone mineral metabolism use alcohol organ transplant form thyroid disease medical condition know associated bone loss</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>HCV</keyword>
	<keyword>hepatitis C virus</keyword>
	<keyword>CHC</keyword>
	<keyword>chronic hepatitis c</keyword>
	<keyword>interferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>DEXA</keyword>
	<keyword>BMD</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>osteopenia</keyword>
	<keyword>osteodystrophy</keyword>
	<keyword>osteodensitometry</keyword>
	<keyword>Bone Density</keyword>
	<keyword>Hepatitis , Viral , Human</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>peginterferon alfa-2a</keyword>
</DOC>